Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value

$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen PROCYSBI (cysteamine bitartrate by Year

Name: Amgen PROCYSBI (cysteamine bitartrate by Year (AMGN)
Creator: Amgen

PROCYSBI (cysteamine bitartrate — Nephropathic Cystinosis) — U.S. sales ($M) ($M)

Quarterly Annual

Amgen PROCYSBI (cysteamine bitartrate: $233M in FY2025, up 5.4% from a year earlier.

Latest, FY2025

233

Period ended Dec 31, 2025

Change on a year earlier

+5.4%

221 in FY2024

History

3 years

Since FY2023

Sources

Documents cited below

Where the FY2025 figure comes from

“|| PROCYSBI — U.S. (1) | 233 | 5 | % | 221 | * | 49”

Source: Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗

Reported in Form 10-Q / 10-K Other Product Sales by Geographic Region Footnote.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	PROCYSBI (cysteamine bitartrate — Nephropathic Cystinosis) — U.S. sales ($M) ($M)	Year on year	Source
FY2025	Dec 31, 2025	233	+5.4%	Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
FY2024	Dec 31, 2024	221	+351.0%	Form 10-K (amgn-20241231.htm, filed 2025-02-14) ↗
FY2023	Dec 31, 2023	49	–	Form 10-K (amgn-20231231.htm, filed 2024-02-14) ↗

Breakdown

What makes up PROCYSBI (cysteamine bitartrate

PROCYSBI — Rest of World (ROW) sales ($M)7 · FY2025

Cite this data

StockData. (2026). Amgen PROCYSBI (cysteamine bitartrate ($M), annual FY2023–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-procysbi-us

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.